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neural progenitor cells as well as primary fibroblasts,Autotransplantation for Parkinson's
myoblasts, and astrocytes genetically engineered toDisease Goes a Step Further produce L-DOPA or dopamine. Unfortunately, these
grafts (e.g., adrenal medulla) provide only short-term
and inconsistent clinical benefits (Gage, 1998) or carry
some risk of viral infections.Parkinson's disease (PD) is caused by degeneration of
A potential autologous dopamine source that has re-neuromelanin-containing dopaminergic (DA) neurons in
ceived little attention until recently is the carotid body.the midbrain substantia nigra, which leads to dopamine
The carotid body is located near the bifurcation of thedeficiency in the main dopaminergic innervation targets,
carotid artery and contains dopamine-rich glomus cells.the caudate nucleus and putamen (collectively called
These paraneuronal cells contain chemoreceptors thatthe striatum). Affected individuals, numbering over a
are sensitive to changes in blood oxygen and carbonmillion in North America, typically exhibit tremor, muscu-
dioxide, as well as pH, and they help to regulate respira-lar rigidity, akinesia or bradykinesia (absence or slow-
tion rate (Fidone and Gonzalez, 1987). A decrease inness of voluntary movement), postural instability, and
oxygen pressure at the carotid artery induces these cellsreduced life expectancy. The best current therapy is the
to increase their firing rate and to stimulate medullardopamine supplement L-DOPA (L-dihydroxyphenylala-
neurons that in turn cause a dramatic increase in respira-nine). It is orally active, crosses the blood±brain barrier,
tory rate. Thus, these cells thrive and are activated underand can be converted to dopamine by the enzyme DOPA
the hypoxic conditions that exist in the graft envi-decarboxylase in the remaining DA neurons and possi-
ronment.bly other cell types. Unfortunately, L-DOPA often fails
Carotid bodies are not normally essential becauseto improve tremor, does not always elicit consistent
respiratory rate is independently regulated by carbonresponse, and loses its effectiveness as PD progresses
dioxide± and acid-sensitive receptors in the brain stem.and more of the DA neurons that utilize it degenerate.
Humans survive unilateral and bilateral resection evenL-DOPA also causes significant side effects including
though their responses to hypoxia are significantly de-dyskinesias (abnormal involuntary movements) and psy-
pressed (Honda, 1992). Autologous transplantation, whichchiatric disturbances. Other treatments include dopa-
avoids the problem of immune rejection, is thus a realmine agonists (bromocriptine) and monoamine oxidase
possibility. A further advantage of the carotid body isB (MAO-B) inhibitors (selegiline), which are often effec-
its ability to produce, in addition to dopamine, glial celltive only early in the course of PD (Lang and Lozano,
line±derived neurotrophic factor (GDNF) (Nosrat et al.,1998a, 1998b).
1996), a potent neurotrophic factor that promotes the sur-Because the current therapies do not change the dis-
vival, function, and sprouting of DA neurons.ease progression and ultimately fail to provide relief,
In a previous issue of Neuron (Espejo et al., 1998),novel therapeutic approaches are being investigated.
Lopez-Barneo and colleagues demonstrated that iso-These include compensatory surgical destruction or in-
genic grafts of carotid body, but not control carotidhibitory electrical stimulation of basal ganglia targets
artery fragment grafts, led to improvement in a rat modelsuch as the internal segment of the globus pallidus (re-
of PD that was created by unilateral lesion of DA neuronsducing L-DOPA-induced dyskinesia and other symp-
with 6-hydroxydopamine. Greater than 40% of graftedtoms of PD), the motor thalamus (effective at controlling
tyrosine hydroxylase±positive (TH1) glomus cells sur-tremor), and subthalamic nuclei. In addition, the use of
vived in the rat striatum. Rats with carotid body graftssurvival (neurotrophic) factors for DA neurons (preven-
improved in several behavioral tests. Spontaneous andtion therapy) and transplantation (replacement therapy)
amphetamine-induced turning, which reflects imbal-are under active investigation in animal models and in
ance in dopamine release, was eliminated at 10 days,the clinic (Rosenthal, 1998).
1 month, and 3 months after grafting. In addition, senso-The goal of transplantation is to provide a continuous
rimotor neglect was reduced at 1 and 3 months. How-local cellular source of dopamine in the dopamine-
ever, the distance traveled in the open field, a parameterdepleted caudate and putamen as well as trophic sup-
of bradykinesia, did not improve in these rats. Consis-port to the remaining endogenous DA neurons. Human
tent with the results of the behavioral tests, TH1 fibersembryonic fetal ventral mesencephalic tissue, which
were observed in the grafted striatum, and the reinner-contains DA neurons, has been grafted into the striatum
vated areas showed increased evoked release of dopa-of PD patients. Although these grafts occasionally pro-
mine in vitro 3 months after the transplantation.vide long-lasting clinical benefits (Olanow et al., 1996),
Given the promising results in the rodent model, Lo-they are not readily available. Moreover, even though
pez-Barneo and colleagues have now extended theirin rodent models graft survival can be improved with
studies to a nonhuman primate model of PD (Luquin etantioxidants, caspase inhibitors, neurotrophic factors,
al., 1999 [this issue of Neuron]). They used two Cynomol-and supportive cografts, graft survival in humans is still
gus monkeys that received weekly intravenous injec-poor (z5%). Other tissues and cells that produce dopa-
tions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridinemine are also being tested in animal models and/or
(MPTP) over 10 months. MPTP is converted by MAO-Bpatients with PD. These include adrenal medulla, sym-
pathetic ganglia, porcine embryonic DA neurons, and to 1-methyl-4-phenyl pyridinium (MPP1), which enters
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DA neurons through the dopamine transporter, inter- are quite similar to these obtained with adrenal medul-
lary grafts, which survive poorly but can induce the reap-feres with ATP production in the mitochondria, and leads
pearance of host TH1 fibers (Bohn et al., 1987). Under-to cell death. As a result, these monkeys developed
standing the mechanisms by which the glomus graftsstable and severe bilateral parkinsonism, which mani-
ameliorate PD symptoms in monkeys may enable theirfested in tremor, freezing, impaired balance, poor pos-
better usage and point to novel therapeutic avenues forture, and reduction in spontaneous activity. In addition,
this disorder.the monkey that was trained prior to the MPTP treatment
Regardless of the mechanism, glomus cell transplantson a fine motor task suffered an increase in the number
could become effective therapy for PD in humans. Be-of failures and time to complete the task.
fore clinical trials are attempted, more extensive andThree or seven months after the last MPTP injection,
better controlled trials, as well as direct comparisonsone carotid body was harvested and cut into 0.2±0.3
to fetal DA grafts, must be conducted in primates. Inmm diameter aggregates, and two sites in the left puta-
addition, it will be important to determine whether themen were grafted with three to five aggregates per site.
carotid bodies show degenerative changes in PD pa-One monkey also received a single vehicle injection in
tients, which may have an impact on their use. The newthe right putamen to control for the effects of surgical
results will hopefully prompt additional investigators totrauma. Both monkeys showed improvement that began
study the utility of carotid body grafts and to help deter-2±4 weeks after transplantation and lasted throughout
mine whether they can turn into a clinical reality.the duration of the study (3 or 5 months). Initially, the
monkeys exhibited a reduction in tremor. Subsequently,
they displayed an increase in spontaneous activity, more Derek Choi-Lundberg and Arnon Rosenthal
frequent use of the contralateral limbs, and improve- Department of Neuroscience
ment in posture and balance, resulting in a 40% or 50% Genentech, Incorporated
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mechanism by which the glomus grafts mediate their
beneficial effects. Although the unilateral recovery makes
it unlikely, in light of the fact that only two monkeys
were grafted unilaterally, and only one vehicle-injected Functional Consequences
putamen served as a control, spontaneous recovery of Coincident Expression of EphA
cannot be completely excluded. Alternatively, it is possi-
Receptors and ephrin-A Ligandsble that the high dopamine content of glomus cells en-
ables a small number of them to substitute for thousands
of neurons. Finally, trophic and sprouting-inducing fac-
tors such as GDNF, which are produced by the carotid The Eph family of receptor tyrosine kinases and ligands
bodies and can act on the endogenous DA neurons, are implicated in many developmental phenomena, in-
rather then dopamine may account for the observed cluding axon pathfinding, branching, and topographic
benefits. Changes in the survival and fiber density of mapping (O'Leary and Wilkinson, 1999). The Eph family
the endogenous DA neurons in the grafted monkeys has two subfamilies: the EphA receptors (A1±A8) and
ephrin-A ligands (A1±A5), and the EphB receptors (B1±were not investigated. However, the histological results
